These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9315836)

  • 81. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy.
    Breuer O; Blich O; Cohen-Cymberknoh M; Averbuch D; Kharasch S; Shoseyov D; Kerem E
    Pediatr Pulmonol; 2015 May; 50(5):495-502. PubMed ID: 25652187
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Oral antibiotics for the treatment of severe pneumonia in children.
    Klugman KP; Madhi SA
    Lancet; 2004 Sep 25-Oct 1; 364(9440):1104-5. PubMed ID: 15451204
    [No Abstract]   [Full Text] [Related]  

  • 83. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
    Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
    Rhew DC; Hackner D; Henderson L; Ellrodt AG; Weingarten SR
    Chest; 1998 Jan; 113(1):142-6. PubMed ID: 9440581
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 86. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
    Kuti JL; Capitano B; Nicolau DP
    Pharmacoeconomics; 2002; 20(8):513-28. PubMed ID: 12109917
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Community-acquired pneumonia.
    Niederman MS
    Isr Med Assoc J; 2003 Feb; 5(2):133-8. PubMed ID: 12674669
    [No Abstract]   [Full Text] [Related]  

  • 88. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of guidelines on outcome: the evidence.
    Martínez R; Reyes S; Lorenzo MJ; Menéndez R
    Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Community-acquired pneumonia: need for a cost-effective approach to treatment.
    Prabhudesai PP; Kuruvilla T; Tadvi S
    Chest; 1997 Sep; 112(3):861-2. PubMed ID: 9315836
    [No Abstract]   [Full Text] [Related]  

  • 91.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.